Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges

Valenzuela, Fernando; Fernández, Javier D.; Cea, Mauricio Sánchez; Zamudio, Andrea

doi:10.1590/abd1806-4841.20187387

Cited by 7 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22] Erythrodermic psoriasis is considered an acute condition in which >90% of the body is covered with inflamed surfaces and is considered a skin marker of HIV infection when occurs in recalcitrant psoriasis or in previously healthy patients. [23,24] Archives of Pharmacy Practice ¦ Volume 12 ¦ Issue 1 ¦ January-March 20211…”

Section: Reviewmentioning

confidence: 99%

A review on updates in management and Treatment of Psoriasis

Alhammad¹,

Aseri²,

Alqahtani³

et al. 2021

Arch Pharma Pract

View full text Add to dashboard Cite

Introduction: Introduction: Psoriasis is a rather common inflammatory skin disease that is characterized by the appearance of red scaly plaques and may affect any part of the body. There are certain factors that make psoriasis a challenge for physicians, these include: high prevalence, disability, chronicity, disfiguration, and associated comorbidities. The approach to the management of Psoriatic patients should also take into account the dermatological clinical features. This review would discuss and focus on recent updates in the management of Psoriatic patients and its common related issues as well as the clinical picture of psoriasis in order to understand and inform medical practitioners and develop their knowledge of the etiology of the condition, immune and environmental factors, has led to the development of precision-targeted therapies that alleviate patient morbidity. Methodology: PubMed database was searched and screened for relevant observational studies, systematic reviews, randomized controlled trials, meta-journal articles, and journal articles containing the term used in the mesh "Psoriasis", "Management" "Treatment trials" within the title or abstract. Conclusion: The physician should adhere to updated evidence-based guidelines in the management of psoriatic patients. New biologic modalities and alternative nature-based treatments for psoriasis should be studied. Pharmacodynamics profiles, administration modality, and dosing regimens for the currently available IL-17 and IL-23 inhibitors must be reexamined to improve the overall continuity of care of psoriasis patients.

show abstract

Section: Reviewmentioning

confidence: 99%

A review on updates in management and Treatment of Psoriasis

Alhammad¹,

Aseri²,

Alqahtani³

et al. 2021

Arch Pharma Pract

View full text Add to dashboard Cite

show abstract

“…2 Several articles reported EP triggered by infection, such as HCV and HIV infection. 47,73,106 agents compared to conventional oral agents, their use in patients with viral hepatitis and HIV remains limited. Drug survival is impaired in EP compared to plaque-type psoriasis in post-marketing studies.…”

Section: Discussionmentioning

confidence: 99%

“…Both etretinate and its active metabolite acitretin are often used for the treatment of EP, [33][34][35]37,[40][41][42][43][44][45]47 but the results have been inconsistent. Kim et al reported satisfactory outcomes for 12 patients with a monotherapy of acitretin, 40 10 (83.3%) patients reported remission under the initial dose of 20-60 mg daily.…”

Section: Acitretin/etretinatementioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

show abstract

“…Retinoids have long been used in treatment of malignancies (15)(16)(17)(18) and dermatological diseases (19)(20)(21)(22)(23)(24)(25)(26). All trans retinoic acid (ATRA) (t 1/2 0.5-2h) is used in high-dose pulsed regimens to treat acute promyelocytic leukemia (16).…”

Section: Retinoids As Therapeuticsmentioning

confidence: 99%

Retinoids: novel potential therapeutics in the pursuit of HIV-1 cure

Purssell¹,

McGuinty²,

Vulesevic³

et al. 2022

Front. Virol.

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) infection remains a global epidemic. While antiretroviral therapy (ART) suppresses viral replication, cessation of ART results in viral rebound necessitating lifelong treatment. This is a result of a reservoir of latently infected cells, resistant to clearance by ART and the major obstacle in curing HIV. HIV cure strategies have focused on reactivating this latent reservoir with latency reversal agents (LRAs) along with enhancement of anti-HIV immunity to eliminate reactivated HIV. Retinoic acid (RA) derivatives are promising therapeutics that may promote clearance HIV latent reservoir allowing for definitive cure. In addition to plausible mechanisms for depleting the latent reservoir with LRA activity via the p300 acetyl transferase pathway, countering HIV-mediated suppression of RIG-I and IRF-3, and proposed induction of selective apoptosis of HIV-infected cells via RIG-I, RA may also limit HIV spread by augmenting cellular trafficking via CCR7 and CCR9 and induce accumulation of high-affinity effector CD8+ T cells that aid immune clearance of HIV-infected cells. Furthermore, due to their specificity for HIV-infected cells, retinoids are attractive agents to form the basis of multidrug regimens. Altogether, retinoids have many compelling properties as potential novel therapeutics in the cure of HIV.

show abstract

Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges

Cited by 7 publications

References 9 publications

A review on updates in management and Treatment of Psoriasis

A review on updates in management and Treatment of Psoriasis

Updates on the Treatment of Erythrodermic Psoriasis

Retinoids: novel potential therapeutics in the pursuit of HIV-1 cure

Contact Info

Product

Resources

About